Overview

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®

...
More »
Stock Quote
NASDAQ - CDXC
Price$3.56
Change (%) Stock is Down 0.08 (2.20%)
Volume176,823
Refresh quote
Real-Time Level 2 Quote
Recent NewsMore »
DateTitle 
06/04/18ChromaDex Appoints Lisa Bratkovich as Chief Marketing Officer
IRVINE, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Lisa Bratkovich as Chief Marketing Officer, effective today. Bratkovich is joining ChromaDex from Direct Upside Group, a direct-to-consumer marketing and customer experience transformation consulting firm, where she has served as CEO and Principal since 2016. Prior to starting her o... 
Printer Friendly Version
05/29/18TRU NIAGEN® to be featured at the American Society for Nutrition's Annual Meeting
ChromaDex Chief Scientific Advisor, Charles Brenner, PhD, to discuss nicotinamide riboside in educational session IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it will feature its novel form of vitamin B3, TRU NIAGEN® (Booth #405), at the American Society for Nutrition's Annual Meeting, a gathering of 2500 scientists, healthcare practitioners, res... 
Printer Friendly Version
05/14/18ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board
World-Renowned British Chemist to Assist in Uncovering New Applications for Nicotinamide Riboside and Mitochondrial Health IRVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that it has appointed Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of  Cambridge, England, to the Scientific Advisor... 
Printer Friendly Version
What's New
Download DocumentationMarch 2018 Investor Presentation
Download DocumentationQ1 2018 Earnings Presentation
Download Documentation2018 Q1 Quarterly Report on Form 10Q
Download Documentation2018 Proxy Statement
Download Documentation2017 Annual Report on Form 10K
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Chromadex Corp posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.